These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients. Saravolatz LD; Markowitz N; Collins MS; Bogdanoff D; Pennington JE J Infect Dis; 1991 Oct; 164(4):803-6. PubMed ID: 1910070 [TBL] [Abstract][Full Text] [Related]
10. [A human monoclonal antibody cocktail for experimental mouse infection with clinically isolated strains of Pseudomonas aeruginosa]. Miura S; Ishibashi Y; Arai T Kansenshogaku Zasshi; 1993 Dec; 67(12):1167-71. PubMed ID: 8294765 [TBL] [Abstract][Full Text] [Related]
11. Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa. Sawada S; Kawamura T; Masuho Y; Tomibe K J Infect Dis; 1985 Nov; 152(5):965-70. PubMed ID: 3930629 [TBL] [Abstract][Full Text] [Related]
13. Targeting of Pseudomonas aeruginosa in the bloodstream with bispecific monoclonal antibodies. Lindorfer MA; Nardin A; Foley PL; Solga MD; Bankovich AJ; Martin EN; Henderson AL; Price CW; Gyimesi E; Wozencraft CP; Goldberg JB; Sutherland WM; Taylor RP J Immunol; 2001 Aug; 167(4):2240-9. PubMed ID: 11490011 [TBL] [Abstract][Full Text] [Related]
14. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization. Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420 [TBL] [Abstract][Full Text] [Related]
15. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. Frank DW; Vallis A; Wiener-Kronish JP; Roy-Burman A; Spack EG; Mullaney BP; Megdoud M; Marks JD; Fritz R; Sawa T J Infect Dis; 2002 Jul; 186(1):64-73. PubMed ID: 12089663 [TBL] [Abstract][Full Text] [Related]
16. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605 [TBL] [Abstract][Full Text] [Related]
17. [Effect of the (Fab')2 fragment of the anti-Pseudomonas aeruginosa antibodies on Pseudomonas-induced keratitis in rats]. Ren PX Yan Ke Xue Bao; 1986 Dec; 2(4):255-7. PubMed ID: 3147914 [No Abstract] [Full Text] [Related]
18. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa. Collins MS; Ladehoff DK; Mehton NS; Noonan JS FEMS Microbiol Immunol; 1990 Dec; 2(5-6):263-8. PubMed ID: 2127368 [TBL] [Abstract][Full Text] [Related]
19. Feasibility of prophylaxis and therapy against gram-negative infections by human monoclonal antibodies. Lang AB; Fürer E; Cryz SJ FEMS Immunol Med Microbiol; 1993 Jun; 7(1):9-13. PubMed ID: 8364527 [TBL] [Abstract][Full Text] [Related]
20. Bivalent flagellin immunotherapy protects mice against Pseudomonas aeruginosa infections in both acute pneumonia and burn wound models. Ahmadi H; Behrouz B; Irajian G; Amirmozafari N; Naghavi S Biologicals; 2017 Mar; 46():29-37. PubMed ID: 28065582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]